Autres langues Sankyo Co., Ltd.

Actions

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
1 532 ^JPY	+2,17 %		+2,75 %	-6,88 %

09/05	Sankyo Co. communique ses prévisions de résultats pour l'exercice fiscal se terminant le 31 mars 2025	CI
29/04	AstraZeneca progresse avec les traitements anticancéreux Truqap et Enhertu	AN

Sankyo Co., Ltd. Proposes Dividend for the Year Ending March 31, 2024, Payable on June 28, 2024; Provides Earnings Guidance for the Year Ended March 31, 2025	09/05
Sankyo Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025	09/05
AstraZeneca makes progress with Truqap and Enhertu cancer treatments	29/04
AstraZeneca upbeat as cancer drugs underpin sales growth	25/04
En Direct des Marchés : Hermès, Schneider, Atos, Carrefour, Casino, Sanofi, STMicro, Meta...	25/04
AstraZeneca hails neurological data for Ultomiris, Soliris	08/04
AstraZeneca's, Daiichi's Enhertu receives US FDA approval	08/04
AstraZeneca, Daiichi make US progress with licence approvals	03/04
AstraZeneca and Daiichi make US progress with latest licence approvals	02/04
Final dividend	28/03	FA
AstraZeneca's breast cancer treatment blocked for NHS use in England	05/03
AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment	04/03
Split: 5 for 1	28/02	FA
Nikkei extends record rally on pharma boost	26/02
Nikkei hits record high as index heavyweights advance	26/02
AstraZeneca completes USD1.1 billion acquisition of Icosavax	19/02
AstraZeneca celebrates Tagrisso approval and new data	19/02
Sankyo Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Grow	08/02
Sankyo Co., Ltd. Reports Earnings Results for the Nine Months Ended December 31, 2023	07/02
SANKYO Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	07/02

Aucun résultat pour cette recherche